Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
ADIA Nutrition Inc (OTC Pink: ADIA) has appointed Dr. Monica Sher as one of the Directors of its Medical Division. Dr. Sher will play a important role in establishing policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. With her background in Internal Medicine, Dr. Sher brings extensive experience to advance aHSCT therapies for MS.
In a notable arrangement, Dr. Sher will receive equity in the company instead of a salary, demonstrating her commitment to ADIA's success. She will be compensated per procedure performed. CEO Larry Powalisz expressed confidence that Dr. Sher's expertise will be invaluable as ADIA expands its medical division and aims to provide top-tier care to MS patients.
Adia Nutrition Inc. (OTC Pink: ADIA) has partnered with Cornerstone Marketing Inc to enhance its social media presence and expand advertising efforts for its product line, including Biolete Coffee and Cement Factory. Cornerstone will manage ADIA's social media strategies, aiming to increase brand awareness, engagement, and customer reach across various platforms, including Amazon. The marketing firm will also develop innovative advertising campaigns and leverage influencer marketing to amplify ADIA's message and foster a loyal customer community. This strategic collaboration is expected to drive growth for ADIA's products and increase visibility in the health and wellness market.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the approval of their Biolete Coffee on Amazon, marking a significant expansion for the company. Biolete Coffee, a unique blend of organic protein and mushroom extracts, offers increased energy without the crash associated with energy drinks. The product will be listed as a Prime Product using Fulfillment by Amazon (FBO).
CEO Larry Powalisz expressed excitement about partnering with Amazon, citing its global reach and seamless shopping experience as ideal for introducing Biolete Coffee to health-conscious consumers. The company has already shipped products to Amazon fulfillment centers nationwide, demonstrating their commitment to rapid expansion and accessibility.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced two significant developments in its distribution strategy. Firstly, the company has registered with RangeMe, a product discovery platform that connects them with over 15,000 buyers from major retailers like Walmart, CVS, and 7-11. This move allows ADIA to showcase its innovative product, Biolete, a protein coffee with mushrooms designed for health-conscious consumers.
Secondly, ADIA has submitted an application for Walmart's Open Call event in September, where suppliers can pitch their products directly to Walmart buyers. CEO Larry Powalisz expressed excitement about these opportunities, stating they represent significant steps in expanding distribution channels and potentially securing shelf space at Walmart. These strategic moves align with ADIA's mission to revolutionize the supplement industry and promote health and well-being.
ADIA Nutrition (OTC Pink: ADIA) has announced a strategic partnership with Cement Factory Nutrition, a health and wellness company co-owned by former WWE wrestler Jeff Sciullo (known as Elias). This collaboration aims to diversify and enhance ADIA's product offerings in the nutrition and supplement industry.
The partnership involves key figures from Cement Factory Nutrition, including professional bodybuilder AJ Sims and CEO Tomislav Marjanovic. ADIA's investment will be in the form of Series C Preferred Shares, reflecting Cement Factory Nutrition's confidence in ADIA's growth potential. This move is expected to leverage the expertise and resources of both companies to create innovative nutritional solutions.
ADIA Nutrition Inc. (OTC Pink: ADIA) has secured a $500,000 line of credit from CEO Larry Powalisz to support its strategic growth plan. The funds will be used to establish a clinic specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis (MS) patients and expand its supplement divisions. Powalisz, diagnosed with MS 3.5 years ago, underwent aHSCT treatment in Mexico and has been in remission for 2.5 years. The company aims to make this treatment more accessible and affordable in the US by working with insurance companies. This initiative aligns with ADIA Nutrition's mission to revolutionize healthcare through innovative treatments and provide premium, organic supplements.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the acquisition of Biolete , a company specializing in protein coffee with mushrooms. This strategic move expands ADIA's portfolio in the functional beverage market. The acquisition includes Biolete's trademarks, inventory, customer base, and website. ADIA acquired 100% of Biolete through an equity offer of preferred shares regulated under Rule 144, which doesn't affect current outstanding shares.
Biolete's products combine collagen protein and mushrooms in coffee, offering energy-boosting benefits without negative side effects. The acquisition is expected to immediately contribute to ADIA's earnings and provide new growth opportunities. ADIA plans to integrate Biolete's operations and expand distribution channels to accelerate product adoption.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic restructuring, introducing two new divisions: Medical and Supplement. The Medical Division will focus on a clinic for Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis patients. The Supplement Division aims to acquire or invest in companies producing organic supplements using US manufacturing processes.
CEO Larry Powalisz stated that this restructuring reflects ADIA's commitment to innovation and meeting evolving consumer demands. The company believes these new divisions will drive growth and positively impact individuals' lives. ADIA Nutrition Inc. aims to reinforce its position as a trailblazer in the nutrition industry through this strategic move.